Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study
European Journal of Cancer2016Vol. 62, pp. 28–35
Citations Over TimeTop 10% of 2016 papers
Stéphane Oudard, Lionnel Geoffrois, Aline Guillot, Christine Chevreau, Jean‐Laurent Deville, Sabrina Falkowski, Helen Boyle, Marjorie Baciuchka, P. Gimel, Brigitte Laguerre, Mathieu Laramas, Christian Pfister, Delphine Topart, Frédéric Rolland, Éric Legouffe, Gwénaël Dénéchère, Éric Amela, Sophie Abadie‐Lacourtoisie, Marine Gross‐Goupil
Related Papers
- → Improvement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma(2010)33 cited
- → Ischaemic stroke in a patient on sunitinib: Figure 1(2010)6 cited
- → Sunitinib Versus Interferon Alfa in Metastatic Renal Cell Carcinoma(2021)3 cited
- Sunitinib as a molecular targeting agent in renal cell carcinoma(2009)
- → Table S2 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial(2023)